Peptides for FUS Protein Pathology: Addressing ALS and FTLD

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides offer diverse strategies to combat FUS protein pathology, including inhibiting aggregation, disassembling aggregates, and targeted degradation via PROTACs. These interventions hold promise for treating FUS-associated ALS and FTLD.

Fused in Sarcoma (FUS) protein pathology is a significant contributor to the pathogenesis of certain neurodegenerative diseases, particularly a subset of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Similar to TDP-43, FUS is an RNA-binding protein that, when misfolded and aggregated, forms pathological inclusions in the cytoplasm of neurons and glial cells. This aberrant accumulation disrupts vital cellular processes, leading to neuronal dysfunction and death. Addressing FUS protein pathology is crucial for developing effective treatments for these devastating conditions, and emerging research points to the potential of specific peptides in modulating FUS aggregation and promoting its clearance.

The Pathological Role of FUS Protein

Under normal physiological conditions, FUS is primarily localized in the nucleus, where it plays critical roles in RNA metabolism, including transcription, splicing, and DNA repair. However, in FUS-associated neurodegenerative diseases, FUS translocates to the cytoplasm and forms insoluble aggregates. These cytoplasmic FUS inclusions are neurotoxic, impairing axonal transport, disrupting RNA processing, and contributing to neuronal degeneration. The aggregation of FUS is a central event in the progression of these proteinopathies, making its clearance and aggregation inhibition key therapeutic targets.

Peptide-Mediated Strategies for FUS Pathology

Peptides offer several promising avenues to combat FUS protein pathology:

1. Inhibition of FUS Aggregation and Fibrillization

A primary strategy involves peptides designed to prevent the misfolding and aggregation of FUS protein. These peptides can interact with FUS monomers or early oligomers, stabilizing their native conformation or interfering with the protein-protein interactions that drive aggregation. For instance, studies have explored peptides that can induce the liquid-liquid phase separation of α-synuclein, a mechanism relevant to protein aggregation, suggesting similar approaches could be applied to FUS [JACS, 2025]. Other research has shown that certain peptides can suppress FUS aggregate formation, highlighting their potential as aggregation inhibitors [Kamagata et al., 2021].

2. Disassembly of Pathological FUS Aggregates

Beyond preventing aggregation, some peptides are being investigated for their ability to disassemble pre-formed FUS aggregates. This is particularly important in established disease states where significant protein inclusions have already formed. For example, a low-complexity peptide rich in arginine and glycine (RGG peptide) has been identified as a disassembly factor for mutant FUS, suggesting its potential to break down pathological FUS structures [bioRxiv, 2025]. This approach aims to reverse the accumulation of toxic FUS aggregates and restore cellular function.

3. Targeted Degradation via PROTACs

Similar to the strategies employed for TDP-43, proteolysis-targeting chimeras (PROTACs) represent a powerful tool for the targeted degradation of FUS protein. While direct peptide-based PROTACs for FUS are still an active area of research, the success with TDP-43 PROTACs suggests a viable pathway. These bifunctional molecules could recruit E3 ubiquitin ligases to FUS, leading to its ubiquitination and subsequent proteasomal degradation. This catalytic mechanism offers a highly efficient way to remove pathological FUS from cells.

4. Modulating FUS-RNA Interactions

FUS pathology is intricately linked to its interactions with RNA. Peptides that can modulate these interactions, either by stabilizing healthy FUS-RNA complexes or disrupting aberrant ones, could indirectly influence FUS aggregation and function. For example, frameshift peptides have been shown to alter the properties of truncated FUS proteins, affecting their subcellular distribution and aggregation capacity [An et al., 2020].

Challenges and Future Directions

The development of peptide-based therapies for FUS protein pathology faces challenges common to other neurodegenerative proteinopathies, including optimizing brain penetrance, ensuring specificity for pathological FUS, and maintaining peptide stability. However, the diverse mechanisms of action offered by peptides—from aggregation inhibition and disassembly to targeted degradation—provide a robust platform for therapeutic development. Future research will focus on refining peptide design, developing effective delivery systems, and conducting rigorous preclinical and clinical studies to translate these promising strategies into treatments for FUS-associated ALS and FTLD.

Practical Takeaway

FUS protein pathology is a critical driver of certain forms of ALS and FTLD, characterized by the aggregation of misfolded FUS protein. Peptides offer a versatile and targeted approach to combat this pathology by inhibiting aggregation, disassembling pre-formed aggregates, and potentially facilitating targeted degradation via PROTACs. As practitioners, you'll recognize that these innovative peptide interventions represent a crucial step forward in addressing the root causes of FUS proteinopathies. While still an evolving field, the potential for peptide-based therapies to mitigate FUS pathology offers new hope for patients facing these challenging neurodegenerative conditions.